vs

Side-by-side financial comparison of Largo Inc. (LGO) and MEDICINOVA INC (MNOV). Click either name above to swap in a different company.

MEDICINOVA INC is the larger business by last-quarter revenue ($123.3K vs $87.6K, roughly 1.4× Largo Inc.). Largo Inc. runs the higher net margin — -59.3% vs -2473.6%, a 2414.3% gap on every dollar of revenue.

Largo Inc. is a Canada-based critical minerals producer focused on sustainable vanadium extraction and processing. It operates core production assets in Brazil, supplying high-purity vanadium products for steel manufacturing, grid-scale energy storage, and industrial clients across global markets.

Medicinova Inc. is a clinical-stage biopharmaceutical firm developing novel therapies for unmet medical needs, focusing on immunology, inflammatory disorders and oncology. It operates across North America and Asia, advancing pipeline candidates through clinical trials to serve patients with limited treatment options.

LGO vs MNOV — Head-to-Head

Bigger by revenue
MNOV
MNOV
1.4× larger
MNOV
$123.3K
$87.6K
LGO
Higher net margin
LGO
LGO
2414.3% more per $
LGO
-59.3%
-2473.6%
MNOV

Income Statement — Q3 FY2025 vs Q3 FY2025

Metric
LGO
LGO
MNOV
MNOV
Revenue
$87.6K
$123.3K
Net Profit
$-52.0K
$-3.1M
Gross Margin
Operating Margin
-2741.7%
Net Margin
-59.3%
-2473.6%
Revenue YoY
Net Profit YoY
-6.9%
EPS (diluted)
$-0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LGO
LGO
MNOV
MNOV
Q3 25
$87.6K
$123.3K
Q2 25
$54.4K
$134.6K
Q1 25
$28.2K
Q3 24
$100.7K
Q2 24
$70.7K
Q1 24
$42.2K
Net Profit
LGO
LGO
MNOV
MNOV
Q3 25
$-52.0K
$-3.1M
Q2 25
$-40.0K
$-3.3M
Q1 25
$-18.3K
Q3 24
$-18.7K
Q2 24
$-3.9K
Q1 24
$715
Operating Margin
LGO
LGO
MNOV
MNOV
Q3 25
-2741.7%
Q2 25
-2679.9%
Q1 25
Q3 24
Q2 24
Q1 24
Net Margin
LGO
LGO
MNOV
MNOV
Q3 25
-59.3%
-2473.6%
Q2 25
-73.6%
-2437.7%
Q1 25
-64.9%
Q3 24
-18.6%
Q2 24
-5.6%
Q1 24
1.7%
EPS (diluted)
LGO
LGO
MNOV
MNOV
Q3 25
$-0.06
Q2 25
$-0.07
Q1 25
Q3 24
Q2 24
Q1 24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LGO
LGO
MNOV
MNOV
Cash + ST InvestmentsLiquidity on hand
$32.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$44.0M
Total Assets
$47.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LGO
LGO
MNOV
MNOV
Q3 25
$32.6M
Q2 25
$34.3M
Q1 25
Q3 24
Q2 24
Q1 24
Stockholders' Equity
LGO
LGO
MNOV
MNOV
Q3 25
$44.0M
Q2 25
$46.9M
Q1 25
Q3 24
Q2 24
Q1 24
Total Assets
LGO
LGO
MNOV
MNOV
Q3 25
$47.6M
Q2 25
$49.8M
Q1 25
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LGO
LGO
MNOV
MNOV
Operating Cash FlowLast quarter
$-1.7M
Free Cash FlowOCF − Capex
$-1.7M
FCF MarginFCF / Revenue
-1383.5%
Capex IntensityCapex / Revenue
2.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LGO
LGO
MNOV
MNOV
Q3 25
$-1.7M
Q2 25
$-2.3M
Q1 25
Q3 24
Q2 24
Q1 24
$5.0K
Free Cash Flow
LGO
LGO
MNOV
MNOV
Q3 25
$-1.7M
Q2 25
Q1 25
Q3 24
Q2 24
Q1 24
FCF Margin
LGO
LGO
MNOV
MNOV
Q3 25
-1383.5%
Q2 25
Q1 25
Q3 24
Q2 24
Q1 24
Capex Intensity
LGO
LGO
MNOV
MNOV
Q3 25
2.4%
Q2 25
Q1 25
Q3 24
Q2 24
Q1 24
Cash Conversion
LGO
LGO
MNOV
MNOV
Q3 25
Q2 25
Q1 25
Q3 24
Q2 24
Q1 24
6.93×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons